Imaging gut and joint inflammation with adalimumab and a light tracer
Part of Bones, joints & muscles, Digestive system, Immune system & allergy, Skin clinical trials.
This study uses a special “light tracer” medicine with adalimumab to see where inflammation is in the gut (IBD) or joints (RA). If you have active disease, it may help doctors better target treatment by showing inflammation more clearly during scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of either IBD or rheumatoid arthritis (RA)
- Your disease is currently active (for IBD, stool inflammation or symptoms; for RA, painful/swollen hand joint activity)
- You are age 18 or older and able to understand and consent to the study
- If you have IBD, you already have an ileocolonoscopy scheduled for a medical reason
- For women who could become pregnant, you must have a negative pregnancy test and use effective birth control during the study and for 3 months after
- You must not be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study uses special imaging to look at lymph vessels in people with rheumatoid arthritis (RA). The goal is to better understand changes in the lymph system in early versus long-standing RA and during certain treatments.
This study tests whether a special scan can help doctors decide if you can safely reduce your rheumatoid arthritis medication. It may help you taper your treatment while keeping your disease under control.
This study uses advanced imaging and protein tests on tissue samples to see how well treatments work in children with inflammatory bowel disease (IBD). It aims to help doctors personalize care and improve outcomes.
This trial tests whether transferring healthy gut bacteria from a donor to patients with rheumatoid arthritis that hasn't improved on standard medications can reduce joint pain and swelling. The goal is to see if rebalancing the gut microbiome (the community of bacteria in your intestines) helps control inflammation.
This study tests a new way to see inflammation in the gut during a colonoscopy by using special dye attached to two IBD medications (adalimumab and risankizumab). The dye makes the medication glow under a special camera, which may help doctors see exactly where and how much inflammation is present, potentially guiding better treatment.
This trial tests a new imaging method using a special dye (risankizumab-800CW) to see how risankizumab, a medicine for inflammatory bowel disease, works in the bowel. The goal is to better understand the medicine's effects and help doctors tailor treatments.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.